Daiichi Sankyo's TURALIO, approved by the FDA in 2019 ... for pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas - AstraZeneca's Koselugo, which was approved in 2020.
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback